Home › NCT07213544

Remimazolam vs Propofol in Laser Burn Cases

Comparison of Remimazolam Versus Propofol for Monitored Anesthetic Care in Elective Fractional Ablative CO₂ Laser

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥ 18 years
* Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy

Exclusion Criteria:

* History of previous fractional ablative laser therapy for burn scar
* Procedure expected to last longer than 30 minutes
* Allergy such as dextran 40 or contraindication to either of the study drugs
* Pregnant and/or breastfeeding
* Subjects who are unable to or choose not to give informed consent

About the study

This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).

What is being tested

• Remimazolam besylate (drug)
• Propofol (drug)

Sponsor: Medical University of South Carolina · Participants: 136 · Started: Nov 12, 2025

Contact the study team

• Haley Nitchie · Phone: (843) 792-1869

Official record on ClinicalTrials.gov — NCT07213544

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.